3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
92
Fallopian Tube Neoplasms
25
Breast Neoplasms
21
Endometrial Neoplasms
19
Carcinoma, Ovarian Epithelial
12
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Neoplasms
6
Fanconi Anemia, Complementation Group D1
5
Uterine Cervical Neoplasms
4
Recurrence
4
Neoplasm Metastasis
4
Carcinoma, Renal Cell
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Peritoneal Neoplasms
2
Ovarian Diseases
2
Carcinosarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Relapsed Ovarian Cancers Patients
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Platinum-sensitive Ovarian Cancer
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Interventions
pembrolizumab
3
Paclitaxel
3
Carboplatin
3
niraparib
2
anlotinib
2
Pemetrexed
2
Palliative Care
2
Interviews as Topic
2
Gemcitabine
2
Educational Status
2
Bevacizumab
2
temsirolimus
1
relacorilant
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
lenvatinib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Topotecan
1
Therapeutic Touch
1
Radiotherapy
1
Pregnancy Tests
1
Ocoxin
1
Nivolumab
1
Methods
1
Laparoscopy
1
Human Papillomavirus DNA Tests
1
Fulvestrant
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Female
×
olaparib
×
Gynecologic
×
Clear all
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled